Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy
Top Cited Papers
Open Access
- 1 August 2020
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1874 (1) , 188391
Abstract
No abstract availableKeywords
Funding Information
- National Research Program of China (2017YFA0505803, 2017YFC0908100)
- State Key Project for Infectious Diseases (2018ZX10732202-001)
- National Natural Science Foundation of China (81790633, 81672860, 61922047, 81422032, 81902412)
- National Natural Science Foundation of Shanghai (17ZR143800)
This publication has 89 references indexed in Scilit:
- Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growthJournal of Experimental Medicine, 2012
- Unique Metabolic Pathway of [14C]Lenvatinib after Oral Administration to Male Cynomolgus MonkeyDrug Metabolism and Disposition, 2012
- Signal Transduction by Vascular Endothelial Growth Factor ReceptorsCold Spring Harbor Perspectives in Medicine, 2012
- Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination EfficacyMolecular Therapy, 2011
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular CarcinomaJournal of Clinical Oncology, 2008
- Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteinsCancer Science, 2008
- Hepatocellular Carcinoma: Epidemiology and Molecular CarcinogenesisGastroenterology, 2007
- The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A reviewEuropean Journal of Cancer, 2006
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005